P/B
15,7
Lucid Diagnostics
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
$93M
Market Cap • 11/13/2026
2018
(8 years)
Founded
2021
(5 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
17,1
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
0
EPS
—
Market Cap
Market Cap
93M
EV
93,4M
EV/Revenue
17,2
EV/EBITDA
-1,9
EV/EBIT
-1,8
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-24,2%
Total Yield
-24,2%
Payout
0%
Retained Earnings
-319,4M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
97,5%
Capex/Revenue
5,6%
Capex/D&A
34,5%
Capex/OCF
-0,6%
SBC/OCF
—
% PPE
6,8%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
93,6%
CAGR Op. Income 5Y
22%
CAGR Net Income 5Y
20%
CAGR EPS 5Y
-16%
CAGR OCF 5Y
40,3%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
1,2
Quick Ratio
0,9
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!